Strategic focus ACELYRIN is now part of Alumis and operates within a rapidly advancing TYK2 inhibitor program targeting systemic immune disorders and neuroinflammatory diseases, signaling opportunities to align with Alumis’ clinical development and potential commercialization plans.

Pipeline expansion The pipeline includes envudeucitinib (ESK-001) for plaque psoriasis and SLE, plus A-005 targeting CNS and neuroinflammatory indications, suggesting potential for collaboration in autoimmune and neurodegenerative therapeutic areas.

Clinical milestones Upcoming and recent Phase 3 data presentations and regulatory filings indicate windows for partnerships around pivotal results, enabling BD outreach to co-develop or co-commercialize with a focus on TYK2 inhibitors.

Financial reach Significant funding runway with substantial total funding and revenue activity in 2026, providing capacity for partnership deals, licensing, or joint ventures to advance the TYK2 portfolio.

Technology leverage Utilization of a proprietary data analytics platform and integration of common tech stack elements (Tableau, SAP, Microsoft 365, etc.) suggest readiness for data-driven collaborations, real-world evidence generation, and scalable commercial operations.